NTHI
NASDAQ · Pharmaceuticals
Neonc Technologies Holdings
$3.26
-0.15 (-4.40%)
Financial Highlights (FY 2026)
Revenue
62.4K
Net Income
-95,208,262
Gross Margin
100.0%
Profit Margin
-155,365.5%
Rev Growth
+26.0%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 65.6% | 65.6% |
| Operating Margin | -145,601.0% | -131,042.7% | 28.5% | 22.9% |
| Profit Margin | -155,365.5% | -147,597.2% | 18.7% | 18.2% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 62.4K | 49.5K | 45.52M | 48.53M |
| Gross Profit | 62.4K | 49.5K | 29.85M | 31.83M |
| Operating Income | -90,869,584 | -64,911,997 | 12.96M | 11.13M |
| Net Income | -95,208,262 | -68,011,299 | 8.50M | 8.83M |
| Gross Margin | 100.0% | 100.0% | 65.6% | 65.6% |
| Operating Margin | -145,601.0% | -131,042.7% | 28.5% | 22.9% |
| Profit Margin | -155,365.5% | -147,597.2% | 18.7% | 18.2% |
| Rev Growth | +26.0% | +26.0% | -1.4% | +12.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | — | — | 13.53M | 15.66M |
| Total Equity | — | — | 174.37M | 161.35M |
| D/E Ratio | — | — | 0.08 | 0.10 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -89,225,798 | -67,278,758 | 13.90M | 17.76M |
| Free Cash Flow | — | — | 13.27M | 13.39M |